Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine
Michael Ament, Kathleen A. Day, Virginia L. Stauffer, et al.
The Journal of Headache and Pain (2021) Vol. 22, Iss. 1
Open Access | Times Cited: 25

Showing 25 citing articles:

Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)
Fabrizio Vernieri, Claudia Altamura, Nicoletta Brunelli, et al.
The Journal of Headache and Pain (2021) Vol. 22, Iss. 1
Open Access | Times Cited: 112
Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study
Licia Grazzi, Riccardo Giossi, Danilo Antonio Montisano, et al.
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 11
Effectiveness of anti-CGRP monoclonal antibodies on central symptoms of migraine
Luigi Francesco Iannone, Francesco De Cesaris, Anita Ferrari, et al.
Cephalalgia (2022) Vol. 42, Iss. 13, pp. 1323-1330
Open Access | Times Cited: 30
How to integrate monoclonal antibodies targeting the calcitonin gene-related peptide or its receptor in daily clinical practice
Cindy Tiseo, Raffaele Ornello, Francesca Pistoia, et al.
The Journal of Headache and Pain (2019) Vol. 20, Iss. 1
Open Access | Times Cited: 51
Real-world evidence of galcanezumab for migraine treatment in Japan: a retrospective analysis
Tsubasa Takizawa, Seiya Ohtani, Narumi Watanabe, et al.
BMC Neurology (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 27
Orexins and primary headaches: an overview of the neurobiology and clinical impact
Emily C. Stanyer, Jan Hoffmann, Philip R. Holland
Expert Review of Neurotherapeutics (2024) Vol. 24, Iss. 5, pp. 487-496
Open Access | Times Cited: 5
Hypersensitivity to BKCa channel opening in persistent post-traumatic headache
Haidar Muhsen Al-Khazali, Rune H. Christensen, David W. Dodick, et al.
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 3
Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: perspectives of treating physicians in Germany
Andreas Straube, Philipp Stude, Charly Gaul, et al.
The Journal of Headache and Pain (2021) Vol. 22, Iss. 1
Open Access | Times Cited: 21
Efficacy and safety of eptinezumab in patients with migraine and self-reported aura: Post hoc analysis of PROMISE-1 and PROMISE-2
Messoud Ashina, Peter McAllister, Roger Cady, et al.
Cephalalgia (2022) Vol. 42, Iss. 8, pp. 696-704
Open Access | Times Cited: 15
Reduction in migraine-associated burden after eptinezumab treatment in patients with chronic migraine
Peter McAllister, David Kudrow, Roger Cady, et al.
Cephalalgia (2022) Vol. 42, Iss. 10, pp. 1005-1012
Open Access | Times Cited: 13
Preventive drug treatments for adults with chronic migraine: a systematic review with economic modelling
Hema Mistry, Seyran Naghdi, Anna Brown, et al.
Health Technology Assessment (2024), pp. 1-329
Open Access | Times Cited: 2
Galcanezumab Effects on Migraine Severity and Symptoms in Japanese Patients with Episodic Migraine: Secondary Analysis of a Phase 2 Randomized Trial
Hisaka Igarashi, Mamoru Shibata, Akichika Ozeki, et al.
Neurology and Therapy (2022) Vol. 12, Iss. 1, pp. 73-87
Open Access | Times Cited: 7
Erenumab Decreases Headache-Related Sick Leave Days and Health Care Visits: A Retrospective Real-World Study in Working Patients with Migraine
Henri Autio, Timo Purmonen, Samu Kurki, et al.
Neurology and Therapy (2021) Vol. 11, Iss. 1, pp. 223-235
Open Access | Times Cited: 8
The impact of CGRPergic monoclonal antibodies on prophylactic antimigraine therapy and potential adverse events
Abimael González‐Hernández, Bruno A. Marichal‐Cancino, Carlos M. Villalón
Expert Opinion on Drug Metabolism & Toxicology (2021) Vol. 17, Iss. 10, pp. 1223-1235
Closed Access | Times Cited: 4
Reducing the Impact of Headache and Allodynia Score in Chronic Migraine: An Exploratory Analysis from the Real-World Effectiveness of Anti-CGRP Monoclonal Antibodies Compared to Onabotulinum Toxin A (RAMO) Study
Danilo Antonio Montisano, Riccardo Giossi, Mattia Canella, et al.
Toxins (2024) Vol. 16, Iss. 4, pp. 178-178
Open Access
Effects of fremanezumab on migraine‐associated symptoms and medication use in Japanese and Korean patients with episodic migraine: Exploratory endpoint analysis of a multicenter, randomized, double‐blind, placebo‐controlled trial
Muneto Tatsumoto, Miki Ishida, Katsuhiro Iba, et al.
Headache The Journal of Head and Face Pain (2024)
Open Access
(CGRP) Monocloncal antibodies
Claudia Altamura, Luigi Francesco Iannone, Luisa Fofi, et al.
Elsevier eBooks (2024), pp. 363-394
Closed Access
The 15‐day threshold in the definition of chronic migraine is reasonable and sufficient—Five reasons for not changing the ICHD‐3 definition
Laura H. Fischer-Schulte, Arne May
Headache The Journal of Head and Face Pain (2022) Vol. 62, Iss. 9, pp. 1231-1233
Open Access | Times Cited: 2
Correction to: Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine
Michael Ament, Kathleen A. Day, Virginia L. Stauffer, et al.
The Journal of Headache and Pain (2021) Vol. 22, Iss. 1
Open Access | Times Cited: 1
A eficácia do Galcanezumabe na profilaxia de cefaleia crônica migrânea: uma revisão integrativa
Beatriz de Melo Pessôa, Yasmin Nunes Machado, Layane Xavier Sales, et al.
Brazilian Journal of Development (2023) Vol. 9, Iss. 3, pp. 9490-9509
Open Access
Visual hypersensitivity in patients treated with anti‐calcitonin gene–related peptide (receptor) monoclonal antibodies
Simone de Vries Lentsch, Matthijs J. L. Perenboom, Johannes A. Carpay, et al.
Headache The Journal of Head and Face Pain (2023) Vol. 63, Iss. 7, pp. 926-933
Open Access
Galcanezumab (Emgality)
Reimbursement Team
Canadian Journal of Health Technologies (2022) Vol. 2, Iss. 1
Open Access
Galcanezumab (Emgality)
Reimbursement Team
Canadian Journal of Health Technologies (2022) Vol. 2, Iss. 3
Open Access
Helping patients move forward following traumatic brain injury
Imbesi
The Journal of Family Practice (2022) Vol. 71, Iss. 5
Open Access
Eficacia y seguridad del fremanezumab según datos de la vida real
Jésica García Ull
Kranion (2022) Vol. 17, Iss. 2
Open Access
Page 1

Scroll to top